Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

v3.21.1
Acquisitions - Narrative (Details)
3 Months Ended
Oct. 01, 2020
USD ($)
Sep. 09, 2020
USD ($)
Sep. 08, 2020
USD ($)
Apr. 01, 2020
USD ($)
Mar. 31, 2021
USD ($)
Pfenex          
Business Acquisition [Line Items]          
Consideration transferred in acquisition $ 465,100,000        
Cash payments for acquisition 429,600,000        
Contingent earn-out payment 77,800,000        
Fair value of contingent earn-out payment 37,000,000.0        
Post-combination expense 1,500,000        
Gross payments to acquire business attributable to vested portion of stock options $ 17,300,000        
Cash to settle unvested stock options recognized as share-based compensation expense         $ 8,700,000
Weighted-average estimated useful life of finite-lived intangible assets acquired 13 years        
Deferred tax liability acquired in connection with the acquired intangibles $ (53,296,000)        
Deferred revenue acquired $ (3,908,000)        
Pfenex | Discount Rate          
Business Acquisition [Line Items]          
Contingent consideration liability, measurement input (as a percent) 0.071        
Pfenex | Contractual Relationships          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired $ 362,000,000        
Weighted-average estimated useful life of finite-lived intangible assets acquired 12 years 10 months 24 days        
Pfenex | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired $ 23,000,000        
Pfenex | Core Technology | Minimum          
Business Acquisition [Line Items]          
Discount rate used to value intangible assets acquired (as a percent) 12.00%        
Pfenex | Core Technology | Maximum          
Business Acquisition [Line Items]          
Discount rate used to value intangible assets acquired (as a percent) 15.00%        
Taurus          
Business Acquisition [Line Items]          
Consideration transferred in acquisition   $ 5,100,000      
Cash payments for acquisition   4,600,000      
Contingent earn-out payment   0      
Holdback from acquisition   500,000      
Tangible assets acquired   50,000.00      
Taurus | Contingent Value Right for Internal Research and Development          
Business Acquisition [Line Items]          
Contingent earn-out payment   4,500,000      
Taurus | Contingent Value Right on Product Revenues          
Business Acquisition [Line Items]          
Contingent earn-out payment   $ 25,000,000.0      
Proportion of milestone payments (as a percent)   25.00%      
Taurus | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired   $ 5,000,000.0      
Weighted-average estimated useful life of finite-lived intangible assets acquired   10 years      
xCella          
Business Acquisition [Line Items]          
Consideration transferred in acquisition     $ 7,100,000    
Contingent earn-out payment     0    
Holdback from acquisition     500,000    
Tangible assets acquired     200,000    
Liabilities assumed     (100,000)    
Deferred tax liability acquired in connection with the acquired intangibles     (800,000)    
xCella | Earnout Rights for Partner Research and Development          
Business Acquisition [Line Items]          
Contingent earn-out payment     5,000,000.0    
Earnout rights recognized         $ 200,000
xCella | Milestone Payments          
Business Acquisition [Line Items]          
Contingent earn-out payment     $ 25,750,000    
Proportion of milestone payments (as a percent)     25.00%    
xCella | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired     $ 7,800,000    
Weighted-average estimated useful life of finite-lived intangible assets acquired     15 years    
Icagen          
Business Acquisition [Line Items]          
Consideration transferred in acquisition       $ 19,900,000  
Cash payments for acquisition       15,100,000  
Contingent earn-out payment       25,000,000.0  
Fair value of contingent earn-out payment       4,800,000  
Finite-lived intangible assets acquired       $ 12,800,000  
Weighted-average estimated useful life of finite-lived intangible assets acquired       9 years 8 months 12 days  
Tangible assets acquired       $ 1,800,000  
Liabilities assumed       (800,000)  
Acquisition related costs       0  
Deferred revenue acquired       (3,700,000)  
Deferred tax assets acquired       800,000  
Goodwill acquired       9,000,000.0  
Icagen | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired       $ 1,700,000  
Weighted-average estimated useful life of finite-lived intangible assets acquired       10 years  
Discount rate used to value intangible assets acquired (as a percent)       17.00%  
Icagen | Customer Relationships          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired       $ 11,100,000  
Weighted-average estimated useful life of finite-lived intangible assets acquired       9 years 7 months 6 days  
Discount rate used to value intangible assets acquired (as a percent)       17.00%